Everything below concerns incretin. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-26. Numbers and descriptions here follow the published literature rather than marketing material.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
| Property | Value | Notes |
|---|---|---|
| Molecular class | 31-amino-acid peptide | Modified glucagon-like peptide-1 analogue |
| Molecular mass | approximately 4114 Da | Calculated for the free peptide backbone |
| Appearance | white to off-white powder | Typical of purified lyophilised peptide batches |
| Solubility class | freely soluble in water | Aqueous solubility improves at slightly alkaline pH |
| Typical storage | -20 degrees Celsius, dry, dark | Protect from repeated freeze-thaw cycles |
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Reverse-phase high-performance liquid chromatography is the standard method for purity assessment, separating the peptide from truncated or oxidized variants. Mass spectrometry confirms molecular mass and detects modifications, while ultraviolet absorbance near 280 nanometers supports concentration measurement through tryptophan and tyrosine residues. Circular dichroism can indicate secondary structure, though the peptide is largely helical in solution, and ion-exchange chromatography resolves charge variants. Purity values above 95 percent are typical for research-grade material. Stability studies track degradation over time under defined conditions.
Lyophilized semaglutide is typically stored at temperatures between minus 20 and minus 80 degrees Celsius for long-term preservation. Short-term storage at 2 to 8 degrees Celsius is common for working aliquots. Repeated freeze-thaw cycles can degrade the peptide and are usually avoided. The molecule is hygroscopic in its solid form, so containers should remain sealed with desiccant. Solutions are less stable than powders and are generally prepared fresh. Light exposure is limited because aromatic residues can undergo photo-oxidation.
Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 or 280 nanometres is widely used to assess purity and to resolve related impurities. Liquid chromatography coupled to mass spectrometry confirms identity through the protonated molecular ion and fragment ions formed in tandem experiments. Capillary electrophoresis and peptide mapping after enzymatic digestion supply complementary information on charge variants and modification sites. Circular dichroism and nuclear magnetic resonance can report on secondary structure in solution. Absolute quantification usually depends on an external standard, and reported purity depends on the detection wavelength and integration parameters chosen.
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
Symptoms of episcleritis typically include painless redness of the eye (mild pain is possible but atypical), and watery eyes. The pain of episcleritis is typically mild, less severe than in scleritis, and may be tender to palpation. There are two types of episcleritis: the diffuse type, where the redness involves the entire episclera, and the nodular type, where the redness appears more nodular, involving only a small, well-circumscribed area (sectoral). The diffuse type of episcleritis may be less painful than the nodular type. Sometimes, small nodules are present within the episclera, which move slightly over the sclera with gentle pressure. Discharge is absent with episcleritis, and vision is unaffected. Patients with episcleritis experience far less photophobia than patients with uveitis. Episcleritis does not cause the presence of cells or flare in the anterior chamber of the eye. In 80 percent of cases, episcleritis affects only one eye, whereas scleritis often affects both eyes.
(3) Post- synthetic modification of MOFs increased their functionality by reacting organic units and metal-organic complexes with linkers. (4) Multifunctional MOFs incorporated multiple functionalities in a single framework. Since ligands in MOFs typically bind reversibly, the slow growth of crystals often allows defects to be redissolved, resulting in a material with millimeter-scale crystals and a near-equilibrium defect density. Solvothermal synthesis is useful for growing crystals suitable to structure determination, because crystals grow over the course of hours to days. However, the use of MOFs as storage materials for consumer products demands an immense scale-up of their synthesis. Scale-up of MOFs has not been widely studied, though several groups have demonstrated that microwaves can be used to nucleate MOF crystals rapidly from solution. This technique, termed "microwave-assisted solvothermal synthesis", is widely used in the zeolite literature, and produces micron-scale crystals in a matter of seconds to minutes, in yields similar to the slow growth methods. Some MOFs, such as the mesoporous MIL-100(Fe), can be obtained under mild conditions at room temperature and in green solvents (water, ethanol) through scalable synthesis methods. A solvent-free synthesis of a range of crystalline MOFs has been described. Usually the metal acetate and the organic proligand are mixed and ground up with a ball mill. Cu3(BTC)2 can be quickly synthesised in this way in quantitative yield.
Also in the year 1808, at the conclusion of the Spanish reconquest of Santo Domingo and the repossession of the Eastern half of Hispaniola by Spain, the Governor General of Cuba sent all of the recent arrived refugees back to that colony. In so doing, these immigrants then dismantled their two Lodges they had been operating, Concordia and Perseverancia, and left the island. Many of these refugees moved to New Orleans, Louisiana District by 1809, and the next year, established the Concorde Lodge, No. 117, chartered under the Grand Lodge of Pennsylvania. Later in 1810, with three other Lodges in New Orleans, they established the Grand Lodge of Louisiana. Perseverancia was also reorganized in New Orleans under the name Perseverance Lodge No. 118. The only one of these Lodges that remained in Cuba was the Temple of the Theologic Virtues, and it also changed its name to Spanish; Templo de las Virtudes Teologales. The French members mostly having left the island, the remaining members were mostly Creole.
A seminal work of traditional Chinese medicine was the Huangdi neijing (Yellow Emperor's Inner Canon) compiled between the 3rd and 2nd centuries BC (i.e. originating in the Warring States period), which viewed the human body, its organs and tissues through the lens of the metaphysical five phases and yin and yang, and stated a belief in two circulatory channels of qi vital energy. In surgery, Han dynasty era Chinese texts offered practical advice for certain procedures such as clinical lancing of abscesses. The first known physician in China to describe the use anesthesia for patients undergoing surgery was the Eastern Han physician Hua Tuo (d. 208 AD), who utilized his knowledge of Chinese herbology based in the Huangdi neijing to create an ointment that healed surgical wounds within a month. One of his surgical procedures was the removal of a dead fetus from the womb of a woman whom he diagnosed and cured of her ailments.
Kief is a powder, rich in trichomes, that can be sifted from the leaves, flowers and fruits of cannabis plants and either consumed in powder form or compressed to produce cakes of hashish. The term derives from colloquial Arabic كيف kēf/kīf, meaning pleasure.
Sources: en.wikipedia.org
=== Focus === Bhatt's research spans multiple areas of cardiovascular medicine, with an emphasis on interventional cardiology, acute coronary syndromes, stroke, and heart failure, as well as cardiometabolic risk factors such as dyslipidemia, diabetes, obesity, and chronic kidney disease. Profiles from professional organisations and bibliometric databases describe his work as focusing on clinical trials of antithrombotic agents, lipid-lowering therapies, and glucose-lowering drugs in high-risk cardiovascular populations. In addition to procedural and device-based interventional cardiology, he has co-authored professional society statements and guidelines in cardiology and stroke medicine, including recommendations on the early management of adults with ischaemic stroke that have been cited in subsequent American Heart Association and American Stroke Association documents. According to AD Scientific Index, he ranks among the top 0.1% percent of scientists worldwide in his field based on citation indicators.
Pratt (JP.1), it was entirely due to Collip's expertise that a far less toxic extract from that of Banting and Best's had been produced in just five weeks (p.288). Moreover, he was certain that, without Collip, the Toronto team would never have had an extract that was safe enough to administer to any human being. Also, according to Pratt (pp.286-288), the (pre-Collip) efforts of Banting and Best had been no improvement upon the work of George Ludwig Zuelzer fifteen years earlier: who, despite having been "on the right track" (in relation to recognizing the potential efficacy of a pancreatic extract in the treatment of diabetes mellitus) and, "even with the able assistance of the staff of the Physiological Institute of the University of Berlin as well as that of the trained chemists of the Schering Company over a period of four years [viz., prior to Zuelzer's 1907 publication], had been unable to lessen its toxicity sufficiently to have it employed clinically" (pp.286-288). By 22 February 1922, the Toronto team were reporting that "the effects observed in depancreatized animals have been paralleled in man", that the condition of seven patients had been "favourably influenced" by the daily injection of the extract, and that "the patients themselves report[ed] a subjective subjective sense of well being and increased vigor for a period following the [extract's] administration".
14 April – First Minister Humza Yousaf condemns Iran's attack against Israel, describing it as an "extremely worrying development. 15 April – Police Scotland make their first two arrests for alleged offences breaching the Hunting with Dogs (Scotland) Act 2023. 17 April – MSPs vote to increase the minimum alcohol price by 30% from September, when alcoholic drinks will rise from 50p to 65p per unit, with the increase in line with inflation. 18 April – Peter Murrell, the former chief executive of the Scottish National Party (SNP) and husband of Nicola Sturgeon, is re-arrested by Police Scotland and charged in connection with the embezzlement of funds from the SNP. Murrell also resigns his membership of the SNP. The Scottish Government scraps its target of achieving Net Zero by 2030, as well as annual and interim targets for reducing greenhouse gases, and instead replaces them with a system measuring emissions every five years. Following a review of gender services in England, NHS Scotland pauses the use of puberty blockers for children in Scotland, while Glasgow's Sandyford Clinic says 16- and 17-year-olds will need to wait until they are 18 to be prescribed the drugs. 19 April – At the High Court in Glasgow, Kristofer Johnstone is sentenced to ten years in prison after being convicted of the rape and abuse of two girls between 2003 and 2018. The Scottish Greens announce their intention to hold a vote on whether to stay in government with the Scottish National Party following the SNP's decision to scrap key climate targets.
=== Obesity === In an obese person, excess adipose tissue hanging downward from the abdomen is referred to as a panniculus. A panniculus complicates surgery of the morbidly obese individual. It may remain as a literal "apron of skin" if a severely obese person loses large amounts of fat (a common result of gastric bypass surgery). Obesity is treated through exercises, diet, behavioral therapy, and liposuctions. Reconstructive surgery is one aspect of treatment.
Although the closest counterions partially mask a charged micelle (by up to 92%), the effects of micelle charge affect the structure of the surrounding solvent at appreciable distances from the micelle. Ionic micelles influence many properties of the mixture, including its electrical conductivity. Adding salts to a colloid containing micelles can decrease the strength of electrostatic interactions and lead to the formation of larger ionic micelles. This is more accurately seen from the point of view of an effective charge in hydration of the system.
Sources: en.wikipedia.org
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.
No. It shares high sequence identity but carries non-natural modifications that alter its stability and clearance. The naturally occurring hormone is broken down within minutes, while the synthetic analogue circulates far longer.
Attachment to serum albumin reduces renal filtration of the peptide and shields it from enzymatic breakdown. The consequence is a much longer interval between administrations than unmodified peptides allow. The precise contribution of binding affinity to overall duration is still being quantified.
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and cleared quickly. Semaglutide carries a position 8 substitution that blocks that cleavage and a fatty diacid chain that binds albumin. Together these changes extend its circulating half-life to about one week.